CG Oncology (NASDAQ:CGON) Trading Up 7.9%

Shares of CG Oncology, Inc. (NASDAQ:CGON) were up 7.9% on Tuesday . The company traded as high as $36.67 and last traded at $36.19. Approximately 150,264 shares traded hands during trading, a decline of 76% from the average daily volume of 621,993 shares. The stock had previously closed at $33.54.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CGON shares. Cantor Fitzgerald started coverage on CG Oncology in a research report on Tuesday, February 20th. They set an “overweight” rating and a $75.00 target price for the company. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of CG Oncology in a research report on Thursday, April 4th. Morgan Stanley started coverage on CG Oncology in a research report on Tuesday, February 20th. They set an “overweight” rating and a $55.00 target price for the company. Finally, The Goldman Sachs Group started coverage on CG Oncology in a research report on Tuesday, February 20th. They set a “neutral” rating and a $42.00 target price for the company.

CG Oncology Price Performance

The company has a 50 day simple moving average of $40.85.

Insider Buying and Selling

In related news, CFO Corleen M. Roche acquired 2,000 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was acquired at an average cost of $19.00 per share, with a total value of $38,000.00. Following the completion of the purchase, the chief financial officer now directly owns 2,000 shares in the company, valued at $38,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other CG Oncology news, CFO Corleen M. Roche bought 2,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was purchased at an average cost of $19.00 per share, with a total value of $38,000.00. Following the completion of the purchase, the chief financial officer now owns 2,000 shares in the company, valued at $38,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was acquired at an average cost of $19.00 per share, with a total value of $7,600,000.00. Following the completion of the purchase, the insider now owns 400,000 shares of the company’s stock, valued at approximately $7,600,000. The disclosure for this purchase can be found here. Insiders purchased a total of 666,472 shares of company stock valued at $12,662,968 over the last three months.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.